Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming ...

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most ...

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

The United States Food and Drug Administration (FDA) has approved Lenacapavir (LEN), a long-acting injectable antiretroviral hailed as a breakthrough in HIV prevention. Experts in India have welcomed ...

While Gilead Sciences' HIV prevention drug lenacapavir got approved by the US Food and Drug Administration (FDA), its made- ...

The Food and Drug Administration approved a new vaccine to prevent HIV infection, lenacapavir, a long-acting injection, which ...

FRIDAY, June 20, 2025 (HealthDay News) — A new shot to prevent HIV infection has just been approved — and it only needs to be ...

The new HIV PrEP option could drastically reduce the number of new cases by offering a new alternative to daily pills or every-other-month injections.

The US Food and Drug Administration (FDA) has approved a new shot to prevent HIV, offering a long-acting alternative to daily ...

The recent FDA approval of lenacapavir is encouraging in its promise of long-term HIV prevention but might not be available for the vast majority of people in the US.

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.